Icon’s Strategic Positioning and Undervalued Potential: A Buy Recommendation
Analyst Michael Cherny from Leerink Partners reiterated a Buy rating on Icon (ICLR – Research Report) and decreased the price target to $245.00 ...
TD Cowen cuts ICON stock price target to $254, maintains Buy rating
TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.
Buy Rating on Icon: Navigating Short-term Challenges with Strong Competitive Position and Strategic Initiatives
Michael Ryskin, an analyst from Bank of America Securities, maintained the Buy rating on Icon (ICLR – Research Report). The associated price ...